Alexander Craig, MPhil and Elizabeth Dzeng, MD, PhD, MPH
Responding to “Added Points of Concern about Caring for Dying Patients,” authors argue that physicians’ refusal to prescribe lethal drugs in accordance with states’ death with dignity laws could damage patient-physician relationships and harm patients.
AMA J Ethics. 2018;20(11):E1110-1112. doi:
10.1001/amajethics.2018.1110.
Stephanie L. Samuels, MD and Wilma C. Rossi, MD, MBE
When a parent resists a physician's recommendation for a pediatric patient, physician-parent partnering can promote the patient's best interest and help encourage lifestyle changes.
AMA J Ethics. 2018;20(12):E1126-1132. doi:
10.1001/amajethics.2018.1126
Jane Bartels, MBBS and Christopher J. Ryan, MBBS, MHL
When patients cannot give informed consent or refusal for antipsychotic medication, physicians must meet specific criteria to justify temporarily withholding a diagnosis.
AMA J Ethics. 2018;20(12):E1119-1125. doi:
10.1001/amajethics.2018.1119.
When symptoms of polypharmacy are consistent with those of difficult-to-diagnose disorders, reliable determinations about which drugs are necessary is critical.
AMA J Ethics. 2018;20(12):E1133-1138. doi:
10.1001/amajethics.2018.1133.
Clinicians can practice disability humility by developing social understandings of disability. This can help clinicians improve communication and express respect for patients’ authority about their experiences.
AMA J Ethics. 2018;20(12):E1181-1187. doi:
10.1001/amajethics.2018.1181
Researchers and clinicians face ethical and policy-based challenges in disclosing, preventing and treating psychosis. Which diagnostic labels should be considered to motivate more effective public and professional dialogue about psychosis risk?
AMA J Ethics. 2016;18(6):624-632. doi:
10.1001/journalofethics.2016.18.6.msoc1-1606.
How do we determine what a fair price for a life-saving prescription medication should be? This month, we discuss what is means for a price to be “fair” and explore the current legal and economic landscape of prescription drug pricing in the US.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.